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In 1954 Cline, Houseworth and Pitts reported on an ototoxicity study of 100 patients treated in this institution with intermittent streptomycin.
It was felt that this study should be compared with a similar series treated with streptoduocin, a mixture of equal parts of streptomycin and dihydrostreptomycin, to see if there was any significant difference in a degree or type of ototoxicity.
Materials and Methods A group of 105 hospitalized pulmonary tuberculosis patients were treated for a minimum of eight months and a maximum of 10 months.
These patients were mainly young adult men; all received two grams of streptoduocin intramuscularly every third day for six months after which the dose was reduced to one gram every third day. In addition, all of them received isoniazid and/or para-aminosalicylic acid orally. None in this series had more than 30 days of streptomycin or dihydrostreptomycin or other ototoxic drugs within 12 months prior to the study. Audiometer testing was done with a model H-l maico audiometer, and vestibular function was tested grossly by means of an ice water test, as described in the earlier report. ' Arbitrary criteria for evaluating the degree of dysfunction have been defined as follows:
1. 
4.
Severe-loss of more than 30 or more db and/or nystagmus of less than 50 seconds, including no reaction.
For purposes of evaluation the audiograms have been divided into two groups--the low or conversational frequencies represented by the 512 through 2048 cps range and the high tones represented by the frequencies of 4096 to 8192 cps.
Results
As noted in Table I , 43 (40.9 per cent) of the total series showed either some degree of dysfunction at the end of eight to 10 months of therapy or an increase in their original dysfunction. Eighty-five per cent of these abnormal results revealed only slight dysfunction and 7.5 per cent abnormal tests fell in each of the moderate and marked categories. However, only four (3.8 per cent) of the total series showed any clinical hearing loss during the period of study and in all four instances the clinical degree of loss was slight. No patients in this series suffered dizziness. Our observation showed the majority of the loss occurred in the higher frequencies and was only of slight degree. This was essentially the same experience as noted in the series with streptomycin alone. Only three patients in the entire series showed isolated vestibular dysfunction and this was only of slight degree. Only one showed audio loss and slight vestibular dysfunction.
In this series 70 (66.7 per cent) of the total showed some degree of audiometric hearing loss on the initial examination. However, with but one or two exceptions, none of them had significant clinical loss of hearing to begin with. These patients were deliberately included in the series in order to evaluate the effect of drugs on pre-existing auditory impairment. Table I1 shows the breakdown and follow-up on these cases. I t is to be noted that 71.2 per cent showed no change or better readings a t the end of the study than a t the start, 22.2 per cent were slightly worse, 3.3 per cent were moderately worse and the remaining 3.3 per cent were markedly worse a t the end of the study. It is also worthy of comment that three out of four noted to be moderately worse and three out of the four found to be severely worse were from the group with original hearing impairment. The original hearing loss group also includes three of the four who had some clinical hearing loss during the course of therapy. All of the patients found to be moderately or markedly worse than a t the start of the study had their impairment in the higher frequencies. Furthermore, 19 of the 20 who were slightly worse started off with impairment in the higher frequencies only. Our observations indicate that most of the worsen.. ing was in the group who started off with a slight or moderate impairment in the higher frequencies only. 'Per cent of patients with initial audio loss. **Abnormal testa initially. Table 111 shows the comparison of the results of this study with the previous study using streptomycin alone. I t is to be noted that there has been a slightly higher total incidence of abnormalities on combined therapy However, only 2.85 per cent of the patients on the present study showed vestibular damage alone as compared with the 12 per cent on the streptomycin series, and only 0.95 per cent had both audio and vestibular damage as compared to 8 per cent on the streptomycin alone series. These findings would indicate that there is a total overall increase in hearing damage on streptoduocin therapy when compared with streptomycin therapy alone. However, there is a significant lessening of vestibular damage on combined therapy. These factors are in line with what would be predicted from our knowledge of the drugs and would confirm the fact that there is greater risk to hearing from dihydrostreptomycin with lessened vestibular damage, and that the converse is true of streptomycin alone. I t would seem to us that combined therapy has little to recommend it over streptomycin alone since the decrease in vestibular damage, which is easily compensated for by the individual, is more than offset by the increase in auditory damage due to the addition of dihydrostreptomycin. Actually the clinical impairment on either intermittent streptomycin or streptoduocin has been much less than might be inferred from the laboratory findings.
DECREE OF OTOTOXICITY IN 105 P A T I E S T S TREATED 8-10 MOSTHS WITH INTERMITTENT COMBINATIOS STREPTOMYCIN-DIHYDROSTREPTOJIYCIN THERAPY Number

CONCLUSIONS
One hundred five patients with pulmonary tuberculosis were treated from six to eight months with streptoduocin, a combination of equal parts of streptomycin and dihydrostreptomycin, two grams every third day, for the f i s t six months and one gram every third day thereafter. Audiograms and ice water vestibular studies were done and the results compared with those of a aeries of 100 patients who received streptomycin alone. Of the patients in the present series, 66.7 per cent had some initial hearing loas a s measured by the audiogram. The results in this series have been analyzed as a separate group. It is concluded : (1) The overall incidence of ototoxicity is higher with streptoduocin than with streptomycin alone. (2) The incidence of audiographic abnormalities is in the neighborhood of three times that of streptomycin alone. The incidence of vestibular damage with wmbined therapy is about one-fifth that with streptomycin alone. (3) The above findings are to be expected from the nature of the drugs used and the increase in hearing loss from combined therapy more than offsets any advantages due to lessened vestibular damage. (4) Patients with initial hearing loss in the high frequencies are more prone to further loss as a result of streptoduocin. (5) Despite the large number who showed audiographic changes, only 3.8 per cent of the total series developed clinical loss of hearing. (6) In our experience, streptomycin-dihydrostreptomycin combinations seem to offer no advantage over streptomycin alone from the standpoint of ototoxicity when used in the long term treatment of tuberculosis.
CONCLUSIONES
Durante seis a who meses se trataron 105 enfermos de tuberculosis pulmonar usando estreptoduocina, una combinacidn de partes iguales de estreptomicina y dihidroestreptomicina, dos gramos cada tercer dia por 10s primeros seis meses y un gramo cada tercer dis a partir de entonces. Se hicieron estudios con audiogramas y con pruebas de agua helada para funcidn vestibular y los resultados se compararon con loa de 100 enfermos que uaaron estreptornicina sola.
Segdn 10s audiogramas, 66.7 por ciento de los enfermos de la serie, tenian alguna p6rdida auditiva inicial.
Los resultados de estos grupos se han analizado separadamente. Se concluye: (1) En general la incidencia de obtoxicidad es m l s mayor con la estreptoduocina que con la estreptomicina sola. (2) La incideneia de, anormalidades audiogrlficas eski en las cercanias de tres veces la de la estreptomicina sola. La incidencia de daiio vestibular con el tratamiento 
1966
combinado, es wmo un quinto en comparaci6n con la de la estreptomicina sola. (3) Los hallazgos antes dichos son de esperarse por la naturaleza de Ias drogas usadas y por el aumento de la sordera debida a la terapia combinada, la que supera cualquier ventaja debida a menor dafio vestibular. (4) Los enfermos con algo de deficiencia auditiva antes del uso de las drogas son m L propensos a mayor daiio por la estreptoduocina. (5) A p e a r del gran numero que mostraron cambios audiogrAficos, s610 3.8 por ciento del total de las series presentaron perdida clinica del oido. (6) S&n nuestra experiencia, las combinaciones de estreptomicina dihidroestreptomicina, no ofrecen ventaja sobre la estreptomicina sola desde el punto de vista de la toxicidad auditiva, cuando se usan en tratamientos de tuberculosis a largo plazo. 
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